137 related articles for article (PubMed ID: 11354004)
1. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.
Miller M; Ginalski K; Lesyng B; Nakaigawa N; Schmidt L; Zbar B
Proteins; 2001 Jul; 44(1):32-43. PubMed ID: 11354004
[TBL] [Abstract][Full Text] [Related]
2. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
3. Early onset hereditary papillary renal carcinoma: germline missense mutations in the tyrosine kinase domain of the met proto-oncogene.
Schmidt LS; Nickerson ML; Angeloni D; Glenn GM; Walther MM; Albert PS; Warren MB; Choyke PL; Torres-Cabala CA; Merino MJ; Brunet J; Bérez V; Borràs J; Sesia G; Middelton L; Phillips JL; Stolle C; Zbar B; Pautler SE; Linehan WM
J Urol; 2004 Oct; 172(4 Pt 1):1256-61. PubMed ID: 15371818
[TBL] [Abstract][Full Text] [Related]
4. Activating mutations for the met tyrosine kinase receptor in human cancer.
Jeffers M; Schmidt L; Nakaigawa N; Webb CP; Weirich G; Kishida T; Zbar B; Vande Woude GF
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11445-50. PubMed ID: 9326629
[TBL] [Abstract][Full Text] [Related]
5. MET(PRC) mutations in the Ron receptor result in upregulation of tyrosine kinase activity and acquisition of oncogenic potential.
Williams TA; Longati P; Pugliese L; Gual P; Bardelli A; Michieli P
J Cell Physiol; 1999 Dec; 181(3):507-14. PubMed ID: 10528237
[TBL] [Abstract][Full Text] [Related]
6. Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor.
Santoro MM; Penengo L; Minetto M; Orecchia S; Cilli M; Gaudino G
Oncogene; 1998 Aug; 17(6):741-9. PubMed ID: 9715276
[TBL] [Abstract][Full Text] [Related]
7. Two mutations affecting conserved residues in the Met receptor operate via different mechanisms.
Maritano D; Accornero P; Bonifaci N; Ponzetto C
Oncogene; 2000 Mar; 19(10):1354-61. PubMed ID: 10713677
[TBL] [Abstract][Full Text] [Related]
8. The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.
Medová M; Pochon B; Streit B; Blank-Liss W; Francica P; Stroka D; Keogh A; Aebersold DM; Blaukat A; Bladt F; Zimmer Y
Mol Cancer Ther; 2013 Nov; 12(11):2415-24. PubMed ID: 24061647
[TBL] [Abstract][Full Text] [Related]
9. Tumorigenesis mediated by MET mutant M1268T is inhibited by dominant-negative Src.
Nakaigawa N; Weirich G; Schmidt L; Zbar B
Oncogene; 2000 Jun; 19(26):2996-3002. PubMed ID: 10871851
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the met oncogene unveil a "dual switch" mechanism controlling tyrosine kinase activity.
Chiara F; Michieli P; Pugliese L; Comoglio PM
J Biol Chem; 2003 Aug; 278(31):29352-8. PubMed ID: 12746450
[TBL] [Abstract][Full Text] [Related]
11. Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.
Dixit A; Torkamani A; Schork NJ; Verkhivker G
Biophys J; 2009 Feb; 96(3):858-74. PubMed ID: 19186126
[TBL] [Abstract][Full Text] [Related]
12. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
13. Fishing wild-type sparing inhibitors of proto-oncogene c-met variants in renal cell carcinoma from a curated tyrosine kinase inhibitor pool using analog-sensitive kinase technology.
Wang Z; Jiang M; Feng N; Li C
Biochimie; 2018 Sep; 152():188-197. PubMed ID: 30017898
[TBL] [Abstract][Full Text] [Related]
14. [Oncogenes and thyroid tumors].
Lacroix L; Soria JC; Bidart JM; Schlumberger M
Bull Cancer; 2005 Jan; 92(1):37-43. PubMed ID: 15689324
[TBL] [Abstract][Full Text] [Related]
15. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Duh FM; Chen F; Kishida T; Glenn G; Choyke P; Scherer SW; Zhuang Z; Lubensky I; Dean M; Allikmets R; Chidambaram A; Bergerheim UR; Feltis JT; Casadevall C; Zamarron A; Bernues M; Richard S; Lips CJ; Walther MM; Tsui LC; Geil L; Orcutt ML; Stackhouse T; Lipan J; Slife L; Brauch H; Decker J; Niehans G; Hughson MD; Moch H; Storkel S; Lerman MI; Linehan WM; Zbar B
Nat Genet; 1997 May; 16(1):68-73. PubMed ID: 9140397
[TBL] [Abstract][Full Text] [Related]
16. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation.
Naldini L; Vigna E; Ferracini R; Longati P; Gandino L; Prat M; Comoglio PM
Mol Cell Biol; 1991 Apr; 11(4):1793-803. PubMed ID: 2005882
[TBL] [Abstract][Full Text] [Related]
17. RET-familial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor.
Plaza Menacho I; Koster R; van der Sloot AM; Quax WJ; Osinga J; van der Sluis T; Hollema H; Burzynski GM; Gimm O; Buys CH; Eggen BJ; Hofstra RM
Cancer Res; 2005 Mar; 65(5):1729-37. PubMed ID: 15753368
[TBL] [Abstract][Full Text] [Related]
18. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
[TBL] [Abstract][Full Text] [Related]
19. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
Brasher BB; Roumiantsev S; Van Etten RA
Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
[TBL] [Abstract][Full Text] [Related]
20. Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Kong-Beltran M; Seshagiri S; Zha J; Zhu W; Bhawe K; Mendoza N; Holcomb T; Pujara K; Stinson J; Fu L; Severin C; Rangell L; Schwall R; Amler L; Wickramasinghe D; Yauch R
Cancer Res; 2006 Jan; 66(1):283-9. PubMed ID: 16397241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
